Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Ltd (ASX: IMRN) provides investors and industry stakeholders with timely updates through this centralized news resource. Track the Australian biopharmaceutical innovator's progress in developing oral immunotherapies targeting gastrointestinal and immune-mediated disorders.
Access verified announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Immuron's hyperimmune bovine colostrum platform, product pipeline advancements, and financial disclosures - all essential for understanding the company's position in the immunotherapy sector.
Key focus areas include Travelan® commercialization efforts, research into non-alcoholic fatty liver disease treatments, and novel applications of polyclonal antibody technology. Bookmark this page for efficient monitoring of Immuron's progress in addressing unmet needs across gastroenterology and immunology markets.
Immuron , an Australian biopharmaceutical company, will be presenting at the Emerging Growth Conference on May 8, 2024. Investors, analysts, and advisors can interact with the CEO, Steven Lydeamore, during the live event. Questions can be submitted in advance or during the presentation.
Immuron announces the resignation of Non-Executive Director Stephen Anastasiou to focus on other business interests. Stephen has been with the company since 2013, contributing to the launch of Travelan® in the USA and Canadian markets and dual listing on NASDAQ (IMRN). His departure is aimed at restructuring his business commitments to spend more time with family and pursue personal interests. Immuron Chairman expresses gratitude for Stephen's marketing and clinical contributions and wishes him success in future endeavors.